Latanoprost Case Study
Can latanoprost be considered for treating glaucoma?
Adapted from: Alm A et al. Latanoprost in the treatment of glaucoma. Clin Ophthalmol. 2014 Sep 26;8:1967-85. doi: 10.2147/OPTH.S59162. eCollection 2014.
Introduction:
Elevated intraocular pressure (IOP) is one of the major risk factor for the development and progression of glaucoma. Topical prostaglandins (PGs) that possess powerful ocular hypotensive effects are an important treatment option for glaucoma. Also in the European Glaucoma Society guideline, PGs/prostamides are approved as the first-line treatment for glaucoma because it possess IOP-lowering efficacy, their lack of relevant systemic side effects, their requirement for only once-daily dosing, and their good overall tolerability …show more content…
Objective:
This review focuses on to study the efficacy and tolerability of latanoprost in the management of glaucoma or ocular hypertension.
Method:
Publications from PubMed were searched with names of “latanoprost”, “glaucoma/drug therapy*[MeSH]”, “meta-analysis[publication type]”, “comparative study[publication type]”, and “patient compliance[MeSH]” and more recent studies that were yet to be indexed were identified from ad hoc searches and the author’s own database and were included in this review.
Results:
• Latanoprost in ophthalmology and development for glaucoma treatment:
In 1996, latanoprost (0.005%) was launched and was the first of the currently available topical PGF2αanalogs on the market for glaucoma treatment and it accounts for approximately 65% of PG-analog …show more content…
The elimination half-life was 2–3 hours from the eye and 17 minutes from the circulation. Due to low body weight and small blood volume, the median peak plasma concentration and area under the concentration-time curve after adult dosing were found to be higher in infants less than 3 years old than in older subjects. The reduction in IOP begins after 3-4 hours of latanoprost treatment, reaches a maximum after 8–12 hours, and is maintained for at least 24 hours.
• Efficacy:
Some clinical trials and meta-analysis reported that once-daily topical latanoprost (0.005%) was safe and effective in the short- and long-term treatment of glaucoma or ocular hypertension. However, a review of three masked multicenter Phase III studies in 829 patients with elevated IOP observed that 6 months treatment with latanoprost reduced IOP by 35%, if given in the evening, and by 31%, if given in the morning. Currently, open studies conducted over 2 years and 5 years reported that the reduction in IOP was maintained during long-term treatment with no clinically significant side effects.
• Latanoprost vs. Prostaglandins:
Randomized controlled trial with 411 patients with open-angle glaucoma or ocular hypertension treated for 12 weeks with latanoprost, bimatoprost, or travoprost reported that mean reduction of 8.6±0.3 mmHg with latanoprost and 8.7±0.3
Adapted from: Alm A et al. Latanoprost in the treatment of glaucoma. Clin Ophthalmol. 2014 Sep 26;8:1967-85. doi: 10.2147/OPTH.S59162. eCollection 2014.
Introduction:
Elevated intraocular pressure (IOP) is one of the major risk factor for the development and progression of glaucoma. Topical prostaglandins (PGs) that possess powerful ocular hypotensive effects are an important treatment option for glaucoma. Also in the European Glaucoma Society guideline, PGs/prostamides are approved as the first-line treatment for glaucoma because it possess IOP-lowering efficacy, their lack of relevant systemic side effects, their requirement for only once-daily dosing, and their good overall tolerability …show more content…
Objective:
This review focuses on to study the efficacy and tolerability of latanoprost in the management of glaucoma or ocular hypertension.
Method:
Publications from PubMed were searched with names of “latanoprost”, “glaucoma/drug therapy*[MeSH]”, “meta-analysis[publication type]”, “comparative study[publication type]”, and “patient compliance[MeSH]” and more recent studies that were yet to be indexed were identified from ad hoc searches and the author’s own database and were included in this review.
Results:
• Latanoprost in ophthalmology and development for glaucoma treatment:
In 1996, latanoprost (0.005%) was launched and was the first of the currently available topical PGF2αanalogs on the market for glaucoma treatment and it accounts for approximately 65% of PG-analog …show more content…
The elimination half-life was 2–3 hours from the eye and 17 minutes from the circulation. Due to low body weight and small blood volume, the median peak plasma concentration and area under the concentration-time curve after adult dosing were found to be higher in infants less than 3 years old than in older subjects. The reduction in IOP begins after 3-4 hours of latanoprost treatment, reaches a maximum after 8–12 hours, and is maintained for at least 24 hours.
• Efficacy:
Some clinical trials and meta-analysis reported that once-daily topical latanoprost (0.005%) was safe and effective in the short- and long-term treatment of glaucoma or ocular hypertension. However, a review of three masked multicenter Phase III studies in 829 patients with elevated IOP observed that 6 months treatment with latanoprost reduced IOP by 35%, if given in the evening, and by 31%, if given in the morning. Currently, open studies conducted over 2 years and 5 years reported that the reduction in IOP was maintained during long-term treatment with no clinically significant side effects.
• Latanoprost vs. Prostaglandins:
Randomized controlled trial with 411 patients with open-angle glaucoma or ocular hypertension treated for 12 weeks with latanoprost, bimatoprost, or travoprost reported that mean reduction of 8.6±0.3 mmHg with latanoprost and 8.7±0.3